Millennium declares 7.2% stake in Myriad Genetics
Myriad Genetics, Inc. received an amended Schedule 13G filing showing that funds associated with Millennium now report a sizable passive stake in its common stock.
Rhea-AI Filing Summary
Myriad Genetics, Inc. received an amended Schedule 13G filing showing that funds associated with Millennium now report a sizable passive stake in its common stock. Integrated Core Strategies (US) LLC reports beneficial ownership of 5,183,588 shares, representing 5.6% of the outstanding common stock.
Affiliates Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander each report beneficial ownership of 6,700,158 shares, or 7.2% of the class, with shared voting and dispositive power. The filing is certified as a passive investment, stating the securities were not acquired to change or influence control of Myriad Genetics.
Positive
- None.
Negative
- None.
Insights
Millennium reports a passive 7.2% Myriad Genetics stake via Schedule 13G/A.
The filing shows Millennium-related entities reporting beneficial ownership of 6,700,158 Myriad Genetics common shares, equal to 7.2% of the class, with shared voting and dispositive power. Integrated Core Strategies (US) LLC separately reports 5,183,588 shares, or 5.6%, also with shared powers.
The investors certify their holdings are not for the purpose of changing or influencing control, fitting the passive Schedule 13G framework. Actual market impact depends on how these positions are managed over time, but the disclosure mainly updates ownership transparency rather than signaling a defined corporate action.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake in Myriad Genetics (MYGN) does Millennium report in this Schedule 13G/A?
Is Millennium’s Myriad Genetics (MYGN) position classified as passive or activist?
Who are the reporting persons in the Myriad Genetics (MYGN) Schedule 13G/A?
What event date triggers this Myriad Genetics (MYGN) Schedule 13G/A amendment?
What does Israel A. Englander report regarding Myriad Genetics (MYGN) ownership?
AI-generated analysis. How Rhea-AI works. Not financial advice.